Participated · Series B · Jun 2026

GigaAI (Jijia Vision) develops world models and embodied intelligence systems, publishing GigaWorld (GigaWorld-0, GigaWorld-Policy, GigaWorld-1) and GigaBrain series models and positioning them as core engines for physical AGI. The company has built Maker H01, a high-degree-of-freedom humanoid robot designed for dexterous operation and mobile interaction, and reports commercial implementation in automotive, 3C, warehousing, and home-service scenarios with a target delivery volume in the thousands this year. In autonomous driving the firm released DriveDreamer and related simulators that have served more than 30 leading automotive OEMs and autonomous driving companies. For content production it is developing the Yisu Engine, integrating ultra-long-duration video generation, a real-time 3D world model framework, and 3D human generation tools. GigaAI reports building an industry-leading data base, projecting over 1 million hours of high-quality visual-action data and more than 10 million hours of pre-training data this year. The company was founded in June 2023 and is led by post-90s Tsinghua-educated founder Huang Guan, whose team has achieved top benchmark results (e.g., WorldArena) against major international institutions.

Participated · Series C · Mar 2026

Founded in 2018, ZhiTai Biotech focuses on recombinant protein and peptide drugs aimed at chronic metabolic disorders. Its lead asset, the once-monthly injectable GLP-1 receptor agonist Zoweiglutide (ZT002), produced up to 13.8% weight loss at week 24 in Phase II trials and began a Phase III obesity study in January 2026. Additional pipeline candidates include the oral GLP-1 agonist tablet ZT006 (Phase II for weight loss), the GLP-1/FGF21 dual agonist ZT003 (Phase I for metabolic dysfunction-associated steatohepatitis), and the semaglutide biosimilar ZT001 being co-developed with Tonghua Dongbao and Aimeike. The firm has built proprietary long-acting peptide, oral delivery, protein refolding and fusion protein platforms, notably its QLLong fatty-acid modification technology that extends drug half-life. A commercial production base received approval in late 2025, giving ZhiTai end-to-end capabilities from R&D through manufacturing. The founding team largely hails from Novo Nordisk, led by CEO Dr. Zhang Xujia. Backed by more than RMB 500 million in fresh capital, the company is positioned to advance late-stage trials and prepare for commercialization.

Participated · Series C · Mar 2026

QL Biopharma focuses on innovative drugs for chronic metabolic disorders, building a differentiated pipeline of ultra-long-acting, oral, and multi-target peptides to improve patient compliance. Its lead asset, ZT002 (a once-monthly injectable GLP-1RA), is in Phase III weight-loss trials in China after Phase II data showed 13.8 % weight reduction at 24 weeks with minimal GI-related dropouts. Additional programs include ZT006, an oral GLP-1 receptor agonist in Phase II for obesity, and ZT003, a GLP-1/FGF21 dual agonist in Phase I trials in Australia. The company also licenses its semaglutide biosimilar ZT001 to Tonghua Dongbao and Aimeike for diabetes and weight-management indications. Four in-house technology platforms (QLLong, QLOral, QLFold, and QLFusion) span R&D through commercial-scale production, backed by a recently approved manufacturing facility. Proceeds will accelerate clinical advancement, regulatory filings, and commercialization of its metabolic disease portfolio. No revenue or user metrics were disclosed in the articles.

Participated · Series A · Nov 2023

舶望制药 is an RNAi drug R&D platform that focuses on developing siRNA therapeutics. The company says it will rely on a world-leading drug design and development platform to provide better treatments to patients globally. 舶望制药 recently completed a RMB 300 million A+ financing round. The round was led by Guotou Zhaoshang, with Huagai Capital, Yuanxi Haihe Fund and existing shareholder Sanyi Innovation Investment participating. Proceeds will be used to advance the global development of four clinical pipelines and to discover multiple preclinical candidate (PCC) molecules. The company will also use funds to iterate and upgrade its modification technology platform and extrahepatic delivery technology platform, and to strengthen its professional team.

Participated · Series C · Dec 2022

QiTan Technology develops nanopore-based gene-sequencing instruments and matching reagents and consumables. Its stated applications include non-invasive prenatal testing, IVF, liquid biopsy, newborn screening, research into genetic and rare diseases, and tumor subtyping. The company undertakes independent research and development, manufacturing, and application of its products. On December 28, 2023, QiTan completed a C+ round financing of nearly RMB 100 million. The reported investors in the round are Source Code Capital and Chengdu Bio-city Fund (Guosheng Capital). The article does not disclose operating metrics or further financial terms. QiTan Technology develops, manufactures and commercializes nanopore-based gene sequencing instruments (QNome platform) along with supporting chips and reagents. The company has built a production base in Chengdu’s Tianfu International Bio‑city with nearly ¥200M invested, capable of producing 2,000 sequencers per year and 1 million reagent/chip kits. QiTan reports over 100 institutional customers across research institutes, universities, hospitals, CDCs and other application areas, and employs more than 270 staff with 75% in R&D. It has focused on domestic supply‑chain localization (over 95% domesticized) and holds a patent portfolio of more than 200 IP results, including over 100 invention patents. Following 2021 product commercialization and 2022 market expansion, the company plans to continue完善 its product matrix and accelerate launch of mid- and high-throughput sequencing platforms and additional applications in 2023. The firm emphasizes multidisciplinary talent cultivation to support R&D and mass-production scalability and intends to deepen market expansion and commercial deployment. Qitan develops nanopore gene sequencers that enable applications such as immunotyping, real-time detection of pathogens, tumor genome analysis, and intestinal flora profiling. The company plans to commercialize its nanopore sequencing equipment this year, which would make it the first Chinese firm and only the second in the world to bring fourth-generation sequencing to market. Qitan expects its sequencers to be competitively priced at about CNY100,000 (USD15,630) each, with per-sequencing costs under CNY1,000 (USD156.30), enabling cost savings for small laboratories and research institutes handling limited samples. The firm has completed a Series B financing, providing capital to support its market launch and commercialization. The article situates Qitan within a large addressable market: global DNA sequencing is projected at USD17.6 billion this year and the Chinese market at CNY20.5 billion (USD3.2 billion). It also notes current market concentration, with Illumina holding roughly 80% and having sold USD276 million of sequencers in the first three quarters of last year.